Ashley M Hopkins1, Michael J Sorich1, Ganessan Kichenadasse2,3, Jim Henry Hughes4, John O Miners1, Arduino A Mangoni1, Andrew Rowland1. 1. Department of Clinical Pharmacology, College of Medicine and Public Health, Flinders University, Bedford Park, SA, 5042, Australia. 2. Department of Clinical Pharmacology, College of Medicine and Public Health, Flinders University, Bedford Park, SA, 5042, Australia. ganessan.kichenadasse@flinders.edu.au. 3. Department of Medical Oncology, Flinders Centre for Innovation in Cancer, Flinders Medical Centre/Flinders University, Bedford Park, SA, 5042, Australia. ganessan.kichenadasse@flinders.edu.au. 4. University of South Australia, North Terrace, Adelaide, SA, 5000, Australia.
Abstract
Purpose To validate a plasma vemurafenib steady-state trough concentration (Css,min) threshold that predicts survival outcomes of patients with BrafV600 mutated melanoma. METHODS: A pooled analysis of individual patient data from two advanced melanoma trials involving vemurafenib ± cobimetinib therapy was performed. Day 23 was chosen as the landmark time when steady-state concentration reached. Optimal Css,min threshold was determined via assessment of discriminative performance and model fitting. Association between vemurafenib Css,min and survival was modelled using Cox proportional hazards regression. RESULTS: Vemurafenib plasma concentration data were available for 402 patients who were on stable dose for the first 3 weeks. When compared to a previously described plasma vemurafenib Css,min threshold of 42 mg/L, we identified that a cutoff concentration of 50 mg/L by day 23 was strongly associated with progression-free survival and overall survival. The association remained statistically significant after adjusting for important clinical confounding variables. Sub-group analysis showed that while the addition of cobimetinib resulted in a lower day 23 plasma vemurafenib Css,min, the threshold was still associated with overall survival and not in the monotherapy cohort. CONCLUSION: A plasma vemurafenib Css,min threshold of 50 mg/L is strongly associated with survival outcomes in patients with advanced melanoma. This new threshold needs to be validated prospectively in future studies.
Purpose To validate a plasma vemurafenib steady-state trough concentration (Css,min) threshold that predicts survival outcomes of patients with BrafV600 mutated melanoma. METHODS: A pooled analysis of individual patient data from two advanced melanoma trials involving vemurafenib ± cobimetinib therapy was performed. Day 23 was chosen as the landmark time when steady-state concentration reached. Optimal Css,min threshold was determined via assessment of discriminative performance and model fitting. Association between vemurafenib Css,min and survival was modelled using Cox proportional hazards regression. RESULTS:Vemurafenib plasma concentration data were available for 402 patients who were on stable dose for the first 3 weeks. When compared to a previously described plasma vemurafenib Css,min threshold of 42 mg/L, we identified that a cutoff concentration of 50 mg/L by day 23 was strongly associated with progression-free survival and overall survival. The association remained statistically significant after adjusting for important clinical confounding variables. Sub-group analysis showed that while the addition of cobimetinib resulted in a lower day 23 plasma vemurafenib Css,min, the threshold was still associated with overall survival and not in the monotherapy cohort. CONCLUSION: A plasma vemurafenib Css,min threshold of 50 mg/L is strongly associated with survival outcomes in patients with advanced melanoma. This new threshold needs to be validated prospectively in future studies.
Authors: E Funck-Brentano; J C Alvarez; C Longvert; E Abe; A Beauchet; P Saiag; C Funck-Brentano Journal: Ann Oncol Date: 2015-11-16 Impact factor: 32.976
Authors: L Goldwirt; I Chami; J-P Feugeas; C Pages; F Brunet-Possenti; C Allayous; B Baroudjian; I Madelaine; H Sauvageon; S Mourah; C Lebbé Journal: Ann Oncol Date: 2015-11-16 Impact factor: 32.976
Authors: E Funck-Brentano; J C Alvarez; C Longvert; E Abe; A Beauchet; C Funck-Brentano; P Saiag Journal: Ann Oncol Date: 2015-04-21 Impact factor: 32.976
Authors: N Kramkimel; A Thomas-Schoemann; L Sakji; Jl Golmard; G Noe; E Regnier-Rosencher; N Chapuis; E Maubec; M Vidal; Mf Avril; F Goldwasser; L Mortier; N Dupin; B Blanchet Journal: Target Oncol Date: 2016-02 Impact factor: 4.493
Authors: Antoni Ribas; Rene Gonzalez; Anna Pavlick; Omid Hamid; Thomas F Gajewski; Adil Daud; Lawrence Flaherty; Theodore Logan; Bartosz Chmielowski; Karl Lewis; Damien Kee; Peter Boasberg; Ming Yin; Iris Chan; Luna Musib; Nicholas Choong; Igor Puzanov; Grant A McArthur Journal: Lancet Oncol Date: 2014-07-15 Impact factor: 41.316
Authors: Remy B Verheijen; Huixin Yu; Jan H M Schellens; Jos H Beijnen; Neeltje Steeghs; Alwin D R Huitema Journal: Clin Pharmacol Ther Date: 2017-09-07 Impact factor: 6.875
Authors: Karl D Lewis; James Larkin; Antoni Ribas; Keith T Flaherty; Grant A McArthur; Paolo A Ascierto; Brigitte Dréno; Yibing Yan; Matthew Wongchenko; Edward McKenna; Qian Zhu; Yong Mun; Axel Hauschild Journal: Br J Cancer Date: 2019-08-16 Impact factor: 7.640
Authors: Neeltje Steeghs; Alwin D R Huitema; Stefanie L Groenland; Remy B Verheijen; Markus Joerger; Ron H J Mathijssen; Alex Sparreboom; Jos H Beijnen; Jan H Beumer Journal: Clin Cancer Res Date: 2021-09-21 Impact factor: 12.531